Skip to main content
Homepage
Full 18-step deep-dive · ~20–30 min · a member feature.
AGING Analysis Report
Aug 7, 2026
16 days ago · 100% complete
NOT DEPENDABLE This report predates a filing — its financial basis has been replaced.
Report generated: Aug 7, 2026 · Filing on record since: Aug 19, 2026 · 12 days after
For AI assistants & researchers — machine-readable summary of this page

What this page is: Delvantic's full research page for Progressive Corporation (PGR) — AI-driven forensic equity research: mechanical valuation models (DCF, EPV, anchored-PE, scenario) plus three independent AI lenses (Quality / Value / Sentiment). Everything below is rendered server-side; you are not missing content that requires JavaScript. All scores are predictions and research opinions, not financial advice.

Our current read (analysis of 2026-08-23): Designation Watch · Gem Score +16 (−100…+100 Quality+Value blend) · Quality 80 · Value -36 · Sentiment 9 (timing only, not weighted) · Composite fair value $531.45 vs $215.34 at analysis

Page map (sections in order; each card carries a stable reference-name attribute you can cite):

  • profile-header / price-overview — company profile, live quote, market cap
  • extended-analysisthe core: three AI lens reads with findings, scores, and the analyst memo
  • future-predictions — our forward price-band predictions
  • market-narrative / ai-findings / gpt-critique — narrative context, cross-model findings, and an adversarial critique of our own analysis (near the end of the document)
  • Members-only sections (render as login gates for anonymous readers): price-history, income-trend, key-metrics, financials (statement tables), insider-trading. The analysis above is public; the raw data tables require a free account.

More for machine readers: site briefing at /llms.txt · any ticker resolves at delvantic.com/stock/TICKER · raw inputs are public-company filings and market data (via licensed data feeds); every model, score, lens read, and prediction on this page is Delvantic's own analysis.

Progressive Corporation

PGR NYSE
Financial Services · Insurance - Property & Casualty
Mayfield, OH 44143, United States progressive.com Updated Aug 6, 8:57am
Price
$212.76
Market Cap
$123.7B
Employees
70,053
Beta
0.26
Avg Volume
3,175,121
Last Dividend
$13.90
CEO
Ms. Susan Patricia Griffith

Progressive Corporation is an American insurance holding company specializing in property and casualty coverage for individuals and businesses. The company’s core offerings include personal and commercial auto insurance, residential property insurance, and a range of specialty lines tailored to specific customer needs. Progressive Corporation operates through three primary segments: Personal Lines, Commercial Lines, and Property, serving policyholders through both independent insurance agents and direct channels such as online platforms and call centers. Its product portfolio covers passenger vehicles, motorcycles, recreational vehicles, boats, and commercial vehicles, as well as homeowners and other related property risks. Headquartered in Mayfield Village, Ohio, Progressive Corporation plays a significant role in the U.S. insurance market as one of the largest auto insurers, providing risk protection and claims services that support households, small businesses, and larger commercial clients across diverse geographic markets.

Runs with full report Generated: Aug 7, 2026 12:20am
Price Overview
Price at report time
$215.34
as of Aug 7, 12:20am (16d ago)
Change · Aug 7
+2.58 (+1.21%)
Day Range
$212.62 – $215.37
52-Week Range
$189.20 – $254.93
50-Day MA
$211.66
200-Day MA
$210.56
Volume
1,127,169.00
Right now · live
Log in to get the live feed
Members see the real-time price and the move since this report (over 16d).
Share Structure
Outstanding 581,400,000.00
Float 579,057,910.00
Free Float 99.6%
High free float — 99.6% of shares trade freely, ~0.4% held by insiders/institutions
Very liquid — most shares trade freely. Low insider ownership can mean less management alignment, but makes large position sizing straightforward.
Price History (1 Year)
Last updated: Aug 7, 2026 12:34am (16d ago)
Revenue & Net Income Trend
The directional story — useful even when net income is negative.
Last updated: Aug 6, 2026 8:57am (17d ago)
Revenue
The top line — total sales before any costs or taxes are subtracted. A measure of how much business the company is doing.
Net Income
The bottom line — profit left after subtracting all expenses, interest, and taxes from revenue. Reflects accounting profitability, but includes non-cash items like depreciation, so it isn't the same as cash earned.
Operating Cash Flow
The real cash generated by the day-to-day business — selling products, paying suppliers, collecting from customers. Calculated from net income by adding back non-cash items and adjusting for timing (unpaid bills, unsold inventory). When OCF consistently lags net income, the reported profit may not be converting to real money.
Period Revenue Net Income Net Margin YoY/QoQ
Key Metrics
TD Twelve Data statement HEX SEC filing
Industry comparison last run: Aug 7, 2026 12:19am
P/E Ratio (Price per dollar of earnings)
HEX
Stock Price / EPS (Diluted)
11.20
Stock Price: $212.76
EPS (Diluted): 19.23
P/B Ratio (Price vs net asset value)
HEX
Stock Price / Book Value Per Share
4.18
Stock Price: $212.76
Total Equity: $30.32B
Shares: 588,039,522
EV/EBITDA (Total value vs operating profit)
HEX
Enterprise Value / EBITDA
Market Cap: $123.70B
Total Debt: $0.00
Cash: $138.00M
EBITDA: N/A
EBITDA not available
Enterprise Value (Takeover price (cap + debt - cash))
HEX
Market Cap + Total Debt - Cash
$125.4B
Market Cap: $123.70B
Total Debt: $0.00
Cash: $138.00M
Gross Margin (Revenue left after direct costs)
HEX
Gross Profit / Revenue
Gross Profit: N/A
Revenue: $87.64B
Missing from API: Gross Profit
Operating Margin (Revenue left after all operations)
HEX
Operating Income / Revenue
Operating Income: N/A
Revenue: $87.64B
Missing from API: Operating Income
Net Margin (Revenue left as actual profit)
HEX
Net Income / Revenue
12.9%
Net Income: $11.31B
Revenue: $87.64B
ROE (Profit from shareholder equity)
HEX
Net Income / Total Equity
37.3%
Net Income: $11.31B
Total Equity: $30.32B
ROIC (Profit from all invested capital)
HEX
NOPAT / Invested Capital
Operating Income: N/A
Tax Rate: 20.5%
Equity: $30.32B
Total Debt: $0.00
Cash: $138.00M
Zero debt — invested capital = equity minus cash (very efficient)
Current Ratio (Can it pay short-term bills)
HEX
Current Assets / Current Liabilities
Current Assets: N/A
Current Liabilities: N/A
Missing from API: Current Assets, Current Liabilities
Debt/Equity (Leverage — debt vs equity)
HEX
Total Debt / Total Equity
0.00
Short-Term Debt: $0.00
Long-Term Debt: $0.00
Total Debt: $0.00
Total Equity: $30.32B
Zero debt — this company carries no debt obligations. Strongest possible score.
Rev/Share (Top-line per share)
HEX
Revenue / Shares Outstanding
$149.03
Revenue: $87.64B
Shares: 588,039,522
Book Value/Share (Net assets per share)
HEX
(Total Assets - Total Liabilities) / Shares
$51.57
Total Equity: $30.32B
Shares: 588,039,522
FCF/Share (Real cash generated per share)
HEX
(Operating Cash Flow + CapEx) / Shares
$29.25
Operating CF: $17.55B
CapEx: -$348.00M
Shares: 588,039,522
CapEx is negative (outflow) — added to OCF to get FCF
Div Yield (Annual income from holding)
TD
Last Annual Dividend / Stock Price
6.5%
Last Dividend: $13.90
Stock Price: $212.76
Payout Ratio (Earnings paid out as dividends)
HEX
Dividends Paid / Net Income
Dividends Paid: N/A
Net Income: $11.31B
Dividends paid not available in cash flow statement
Industry Benchmarks
Last run: Aug 7, 2026 12:17am
Compares PGR against LLM-researched typical ranges for its industry. One research call per industry, cached indefinitely — every stock in the same industry reuses the same baseline.
Income Statement (Annual)
Last updated: Aug 6, 2026 8:57am (17d ago)
Metric 2021 2022 2023 2024 2025
Revenue $47.7B $49.6B $62.1B $75.3B $87.6B
Cost of Revenue
Gross Profit
Operating Expenses
Operating Income
Net Income $3.4B $721.5M $3.9B $8.5B $11.3B
EBITDA
EPS $5.69 $1.19 $6.61 $14.45 $19.29
EPS (Diluted) $5.66 $1.18 $6.58 $14.40 $19.23
Balance Sheet (Annual)
Last updated: Aug 5, 2026 9:39am (18d ago)
Metric 2021 2022 2023 2024 2025
Cash & Equivalents $202.1M $220.9M $99.6M $154.0M $138.0M
Total Current Assets
Total Assets $71.1B $75.5B $88.7B $105.7B $123.0B
Current Liabilities
Long-Term Debt
Total Liabilities $52.9B $59.6B $68.4B $80.2B $92.7B
Total Equity $18.2B $15.9B $20.3B $25.6B $30.3B
Retained Earnings $15.3B $15.7B $18.8B $24.3B $27.3B
Cash Flow (Annual)
Last updated: Aug 6, 2026 8:57am (17d ago)
Metric 2021 2022 2023 2024 2025
Operating Cash Flow $7.8B $6.8B $10.6B $15.1B $17.5B
Capital Expenditure -$243.5M -$292.0M -$252.0M -$285.0M -$348.0M
Free Cash Flow $7.5B $6.6B $10.4B $14.8B $17.2B
Acquisitions (net) -$313.2M $0 $0
Net Debt Issued / (Repaid) -$500.0M $1.5B $496.3M $0 $0
Dividends Paid
Stock Buybacks
Net Change in Cash $125.6M $18.8M -$121.3M $54.0M -$16.0M
Growth Trends (YoY %)
Last updated: Aug 6, 2026 8:57am (17d ago)
Metric 2022 2023 2024 2025
Revenue Growth +4.0% +25.2% +21.4% +16.3%
Gross Profit Growth
Operating Income Growth
Net Income Growth -78.5% +440.9% +117.3% +33.3%
EBITDA Growth
Dividend History (Last 20)
Last updated: Aug 5, 2026 9:40am (18d ago)
Date Dividend Declaration Record Payment
2026-07-02 $0.10
2026-04-02 $0.10
2026-01-02 $13.60
2025-10-02 $0.10
2025-07-03 $0.10
2025-04-03 $0.10
2025-01-10 $4.50
2024-10-03 $0.10
2024-07-03 $0.10
2024-04-03 $0.10
2024-01-18 $0.75
2023-10-04 $0.10
2023-07-06 $0.10
2023-04-05 $0.10
2023-01-05 $0.10
2022-10-06 $0.10
2022-07-06 $0.10
2022-04-06 $0.10
2022-01-06 $0.10
2021-12-17 $1.50
0Company Classification 1Industry Landscape 2Company Momentum 3Forward Projection 4aDCF Valuation 4bEarnings Power Value 4cAnchored PE 4dReverse DCF 4eRevenue-Based DCF 4fAnchored P/S 4gScenario Analysis 4hDividend Discount Model 4iBook Value Analysis 4jInsider Activity 4fCash Flow Quality 4gDebt Maturity Risk 4hMacro Environment 4iSector Intelligence 4jRevenue Confidence 4kSensitivity Analysis 4lSector Demand Cycle 5AI Investigation 5bThesis Evaluation 6Valuation Synthesis
computed not applicable not yet run 17 computed · 6 not applicable · 1 not yet run
Narrative Economics
The story the market is telling about this stock — the intangible X-factor (founder mythology, cult dynamics, TAM-of-imagination) that moves price beyond what cash flows alone explain. After Shiller, Narrative Economics.
No narrative profile yet for PGR — it's generated by the pipeline (market-narrative step).
Claude Reading
Independent analyst synthesis · claude-opus-4-7 · generated 2026-08-07 00:33:36
Verdict Fairly valued with modest upside — fair value $230-260 versus $212 spot; dissent from the $621 synthesis, agree with Market Forces that peak-cycle tailwinds are fading and insider selling confirms it.

Looking at the raw tape first: Progressive has compounded revenue from $47.7B (2021) to $87.6B (2025) — an 84% cumulative gain — while net income went from $721M in 2022 to $11.3B in 2025, a 15x recovery from the underwriting-cycle trough. Trailing four quarters annualize to roughly $91B revenue and $11.7B NI. On 581M-ish shares implied by the $123.7B cap at $212.76, that's ~$20 in trailing EPS, so the 11.2x P/E is real, not a data artifact. ROE of 37% with zero debt and $30.3B of equity is genuinely elite. But the quarterly margin trajectory tells the more important story: 14.4% → 12.6% → 11.6% → 14% → 11.6% → 12.7% → 14% — margins are oscillating in a band, not expanding, and Q2'26's 14% is flat versus Q2'25's 14.4%. Revenue YoY (Q2'26 vs Q2'25) is only 7.3%, a sharp deceleration from the 16.3% recent print the momentum module cites and far below the 18.8% four-year CAGR. That's the pivot.

The synthesis verdict of $621 fair value ($871 signal-adjusted) versus a $212 print is absurd on its face and I dissent from it firmly. A DCF that spits out a 3x multiple of current price for a P&C insurer at peak-cycle profitability is almost certainly extrapolating 28.7% FCF CAGR and 70% earnings CAGR forward — but those growth rates are arithmetic artifacts of the 2022 combined-ratio blowout ($721M NI base). Normalize 2022 and the earnings CAGR collapses to maybe 15-20%. The Market Forces module and the Thesis Evaluation (score of +1, essentially balanced) are much closer to reality than the valuation synthesis. The narrative layer honestly diagnoses this: the "75% discount" is not a discount, it's a fundamentals-model error, and the engine's own reasoning admits it.

The contrarian bull case that actually deserves airtime is not the DCF — it's the expense-ratio moat. Progressive's direct/telematics model has structurally 3-5 points of expense-ratio advantage over Allstate and the mutuals, and that gap has widened, not narrowed. If auto pricing stays firm through 2026 (rate filings still flowing through), the 2026 numbers could annualize past $95B revenue and $13B NI, putting the stock at ~9.5x forward — cheap for a 35% ROE compounder with zero leverage. The contrarian bear case is that Q1'26 revenue ($22.19B) was sequentially DOWN from Q4'25 ($22.75B), the first sequential decline in the dataset, and Q2'26's rebound to $23.6B is only modest. Auto insurance shopping activity peaks when rates rise; retention weakens on the back end. Insider activity — five sales in a two-day window in late July 2026 with no offsetting open-market buys — is not neutral, it's a tell. Executives don't sell 60,000 shares in 72 hours at cycle peaks by coincidence.

My read: fairly valued to modestly undervalued, not the mispricing the synthesis claims. At $212, PGR trades at ~11x trailing and roughly 12-13x a normalized 2027 earnings power of $16-17/share. That's a reasonable multiple for a best-in-class P&C franchise but not a screaming buy — the peer group (TRV, ALL, CB) trades 11-14x and Progressive deserves a premium of maybe 2-3 turns, implying fair value in the $230-260 range, not $621. The 6.45% dividend yield print looks like a variable-dividend artifact (Progressive pays an annual variable dividend) and shouldn't be treated as a run-rate — verify before underwriting. I'd be a buyer under $200, a holder $200-240, and a trimmer above $260. The synthesis model is broken here; anyone acting on an $871 price target is going to be very disappointed when 2026 prints a combined ratio in the 89-91 range instead of the 86 that DCF is implicitly assuming.

GPT Reading
Independent reading · gpt-5.4 · generated 2026-08-07 00:33:53
Verdict Undervalued at $213 — not the absurd multi-bagger some models imply, but a best-in-class insurer with sustainable earnings power supports roughly $240-$260 if profits hold near current levels.

Progressive looks like a superb business priced more like a good one. The raw numbers show an insurer that has not merely recovered from a soft patch but has stepped up into a much higher earnings band: net income went from $721.5M in 2022 to $3.90B in 2023, $8.48B in 2024, and $11.31B in 2025. That is not just market beta or a treasury-yield assist; the quarterly run-rate has remained remarkably strong, with the last four quarters producing roughly $11.7B of earnings and quarterly margins staying in an 11.6%-14.4% range. Revenue has also kept climbing, from $75.34B in 2024 to $87.64B in 2025, and the first half of 2026 annualizes above $91B. For a P&C insurer, that combination of premium growth and sustained double-digit net margins is the core fact pattern. At $123.7B market cap and about 11x trailing earnings, the market is still treating a large part of this as cyclical normalization risk rather than giving full credit for a franchise that appears to be taking share while earning very high returns.

The balance sheet and cash profile reinforce that read. Reported debt is zero, equity is $30.32B, and ROE is 37.3%—an extraordinary figure even allowing for favorable cycle conditions. Free cash flow of $17.20B against $11.31B of net income is unusually strong and, while insurer cash flow can be noisy because of float dynamics, it still indicates a business generating substantial cash while barely needing capital spending. On book value, the stock is not optically cheap at 4.18x P/B, but that multiple only looks rich if you assume returns collapse. A company earning 30%+ on equity and compounding book rapidly should not trade anywhere near average insurer multiples. If the current earnings power is even mostly sustainable—say earnings settle in the $9B-$10B range rather than continue rising—today’s price implies a low-teens or even sub-13x multiple on normalized earnings for a category leader with no financial leverage.

What stands out most is how implausible the ultra-bull valuation model is, even though I still land bullish. A fair value of $600-$800 is fantasy for a regulated, cyclical insurer unless one assumes today’s margins and growth persist for a very long time with minimal catastrophe or pricing pressure. That model is over-reading cash flow and under-reading the mean reversion embedded in auto and property insurance. But rejecting the absurd DCF does not push me bearish; it just means the right debate is between “modestly cheap” and “fair,” not “4x upside.” Progressive’s recent price drop from roughly $255 to $213 makes more sense as the market discounting peak underwriting conditions than as a verdict that the franchise has deteriorated. If earnings power is peaking, the stock can still be worth more than today because the current multiple already bakes in a meaningful step-down.

The best bear case is straightforward and serious: nearly every number here is flattered by being on the right side of the underwriting cycle. Earnings CAGR of 70% since 2021 is not a durable operating reality for an insurer; it is a rebound from an abnormally weak 2022 plus aggressive repricing through an inflation shock. Revenue growth is already decelerating at the margin, and if loss-cost trends moderate while competition re-intensifies, premium growth could slow just as margins compress. A 4.2x book multiple leaves little room for underwriting mistakes, reserve slippage, or a bad catastrophe year, and “zero debt” is less meaningful for an insurer than it would be in an industrial because the real economic leverage is embedded in the liability structure. On that reading, 11x trailing earnings may actually be full if those earnings are near peak. The insider selling cluster in late July is not a thesis by itself, but it is consistent with management not viewing the shares as obviously mispriced after the run.

What would change my mind is evidence that the earnings plateau is already breaking. If revenue keeps rising but quarterly net income falls back toward $1.5B-$2.0B for multiple quarters, that would tell me the current 12%-14% net margin regime was cyclical froth, not improved structural economics. Likewise, if 2026 annual earnings look more like $8B than $11B despite continued top-line growth, the stock at $213 is closer to fair value than opportunity. On the other hand, if Progressive can sustain something like $22B-$24B quarterly revenue with net margins still around 11%-13% through the next few reports, then the market is still underestimating how durable this higher earnings base is, and I would expect the stock to work back toward the mid-$240s or better.

Grok Reading
Independent reading · grok-4.5 · generated 2026-08-07 00:34:30
Verdict Undervalued quality compounder at $213 — 11x earnings and 4.2x book underprice durable mid-teens growth and 30%+ ROE; fair value nearer $270–300

Progressive’s numbers tell a story of a franchise that has converted an underwriting hard market into something closer to a structural earnings step-change, not a one-cycle sugar high. Revenue compounded from $47.7B in 2021 to $87.6B in 2025; net income went from a trough $722M in 2022 to $11.3B in 2025, with trailing four-quarter margins locked in the 12–14% band and the most recent quarter printing $23.6B revenue and $3.31B net income at 14%. Free cash flow of $17.2B against a $124B market cap, zero debt, 37% ROE and a 6.5% dividend yield at an 11.2x trailing P/E is not the setup of a fully priced peak-cycle name. The market is effectively capitalizing this run-rate at a discount rate that assumes sharp mean-reversion in underwriting profitability and little durability to the telematics/direct-distribution cost edge. Quarterly revenue is still advancing mid-teens year-over-year even as growth decelerates from the prior explosive pace, which is exactly what a share-gaining compounder should look like once the easy rate-hike tailwind fades.

The valuation synthesis output claiming $622–$871 fair value is not credible and should be discarded; that implies 30–40x earnings on an already-elevated margin base and invents a re-rating the insurance sector has never granted. A more disciplined frame is that Progressive is earning roughly 3x a reasonable cost of equity, which is why it trades at 4.2x book, and that the 11x earnings multiple embeds an expectation of mid-to-high single-digit earnings decline or stagnation. That expectation looks too punitive given $17B of annual FCF, pristine balance sheet, and continued unit growth. Insider sales in late July are noise relative to the cash-generation machine; they do not override the operating evidence.

The strongest counter-argument is straightforward and quantitative: 2022–2025 earnings CAGR of ~70% is almost entirely recovery from a trough combined-ratio disaster, not a new steady state. Net margin at 12.9% and ROE at 37% sit well above Progressive’s own longer-term history; any normalization toward 8–10% margins would cut earnings power to the $7–9B range and make today’s 11x multiple look ordinary-to-rich rather than cheap. Auto frequency/severity inflation, litigation trends, and climate-driven property losses are real, and the market-forces layer correctly flags that forward comparisons get harder from here. Competitors are not static; if State Farm or the nationals reprice aggressively, Progressive’s growth advantage compresses. The decelerating quarterly revenue trend and the thesis score near zero both reflect this legitimate mean-reversion risk. I weigh it as real but already more than discounted at 11x and 1.4x sales for a zero-debt, 18% revenue CAGR franchise still taking share.

What flips the view: two consecutive quarters of combined-ratio deterioration that push net margin sustainably below 10%, or a clear sequential stall in policy-in-force growth below mid-single digits, would force a move to fairly valued or worse. Conversely, another year of 12%+ margins with revenue still above 12% would justify a re-rating toward mid-teens earnings multiples and make the current $213 entry look like a clear miss.

Big-3 Panel — where each AI stands
Each AI above independently stated a direction (undervalued, fairly valued, or overvalued) and how strongly it believes it (conviction, 0–5). We combine those into a Bull-Bear Index on a 0–10 scale: 5 is neutral, 10 is maximum bullish (undervalued at full conviction), 0 is maximum bearish. We compute the score ourselves with the same arithmetic for every seat — the models never grade their own bullishness — so the three are directly comparable. Δ shows how far each seat sits from the panel average of 7.7; a large Δ marks the dissenting voice, usually the one worth reading.
Claude claude-opus-4-7 5.0
fairly valued · conviction 3/5 · Δ -2.7 vs panel · self: 5.0
GPT gpt-5.4 9.0
undervalued · conviction 4/5 · Δ +1.3 vs panel · self: 7.0
Grok grok-4.5 9.0
undervalued · conviction 4/5 · Δ +1.3 vs panel · self: 7.0
Advanced Analysis Forensic deep-dive · separate lenses
Separate reads — Company Quality (is it a great business?), Valuation (is it mispriced?), and General Sentiment (how macro + narrative are pushing it), kept deliberately apart · 2026-08-07 01:02:35
Delvantic - Cairn AI
Quality — starter position, scale in on weakness 7/10
Fortress-quality compounder (Q80) at a fair-to-full price (V-36) with a faint sentiment tailwind — a wait-for-dip name, not a table-pound buy here.
The cruxWhether the auto-underwriting cycle holds near current combined ratios long enough for earnings to grow into the premium multiple before mean reversion hits.
Forensic checks Derived mechanically from PGR's filed financials — not from the AI lenses
Liquidity & RunwaySelf-Funding
DilutionStable Share Count
Earnings QualityHigh Earnings Quality
The four lensesswitch a tab for its full read — score + evidence
Company Quality
+80
Fortress
edge √Σ 144 · risk √Σ 34 · conf 9/10

Progressive has scaled revenue from $47.7B (2021) to $87.6B (2025), an ~16% CAGR, while net income went from $3.35B to $11.31B and FCF from $7.52B to $17.20B — a >2x expansion in three years. OCF/NI of 3.57x and accruals of -6.7% of assets indicate earnings are conservatively stated relative to cash generation (normal for a P&C insurer where float and reserves inflate OCF, but still confirms no aggressive accrual behavior). The 2022 net income trough of $721M reflects the underwriting cycle (catastrophe/loss-ratio pressure) which management has now clearly worked through, with 2024-2025 showing operating leverage on scale. Diluted share count actually declined slightly (592M to 588M, -0.2% CAGR) — per-share value is being protected, not diluted. Liquid cash of $10.1B with $17.2B annual FCF and zero net debt burden means the business is fully self-funding with substantial capital return capacity. The Altman Z of 1.82 (grey) is a quirk of the insurance model (large investment portfolio, low inventory/working capital) and not meaningful here. Insider activity shows routine sales around July equity awards including CEO Griffith — this is programmatic post-vest liquidation, not a red flag, but also no open-market conviction buys.

Strengths 4
m88
Elite revenue and earnings compounding
Revenue 16% CAGR ($47.7B to $87.6B, 2021-2025); net income grew from $3.35B to $11.31B and FCF from $7.52B to $17.20B — evidence of durable share gains in personal auto and operating leverage.
m75
Pristine cash conversion
OCF/NI of 3.57x, accruals -6.7% of assets, FCF ($17.2B) exceeds net income ($11.3B) — no signs of earnings being pulled forward via accruals.
m65
Per-share discipline
Diluted shares went from 592M (2021) to 588M (2025), a -0.2% CAGR — rare for a large-cap financial to hold the line on dilution while growing this fast.
m55
Self-funding balance sheet
$10.1B liquid cash, net cash positive, and $17.2B FCF/yr — the business needs no external capital and has ample capacity for dividends, special dividends, and reserve strength.
Concerns 2
m30
Cyclical earnings volatility
2022 net income collapsed to $721M from $3.35B in 2021 on adverse loss trends before recovering — reminder that P&C underwriting margins are cycle-exposed even for the best operator.
m15
Insider selling, no buying
8 sells totaling $14.7M in trailing 12 months including CEO Griffith ($7.9M), 0 open-market buys. Pattern is consistent with routine post-vest liquidation but there is no insider conviction signal on the buy side.
This is a top-decile P&C operator firing on every quality axis I can measure. Revenue nearly doubled in four years, net income more than tripled, FCF more than doubled, and the share count actually shrank — that combination is rare at any market cap and extraordinary at $120B+. The 2022 earnings dip is a useful reminder that this is still an underwriting business subject to loss-cost cycles, so I stop short of the 92 tier which I reserve for businesses where I can find essentially nothing soft. Insider selling is routine post-vest and doesn't move me. Fortress is the right label for the business itself.
Verify before trusting this (5)
  • Combined ratio trend by segment (personal auto vs commercial vs property) in the 10-K
  • Adequacy of loss reserves and any prior-year development disclosures
  • Investment portfolio composition and credit quality given ~$10B liquid cash figure
  • Whether 10b5-1 plans govern the July insider sales
  • Policy-in-force growth vs rate to distinguish volume from price contribution
Valuation / Mispricing
-36
Fairly Valued
edge √Σ 39 · risk √Σ 77 · conf 7/10
Price $215 vs a credible deserved value in the $215-$270 range (anchored PE $268; composite $622 is not credible) - roughly fair with modest optionality, not a mispricing. attractive below $180.00

The e2e composite fair value of $621.83 and signal-adjusted $871.33 imply 300%+ upside, which fails the sanity check for a $124B P&C insurer already priced at a premium multiple. The DCF at $798.86 requires extrapolating recent hyper-growth (revenue nearly doubled in 4y, earnings tripled) far into the future in a cyclical underwriting business - heroic. The anchored PE of $267.78 is the more credible anchor, implying maybe 20-25% upside if current earnings power holds and normalizes, not a dislocation. Against the $215.34 price, the honest read is that this is a top-decile operator trading at a fair-to-slightly-full multiple after a huge run driven by the hard auto market. Earnings quality is high (no haircut needed) and the business quality is Fortress, both of which raise deserved value - but the market already knows this. The bear case is not that PGR is bad, it is that perfection is priced: loss-cost inflation, litigation trends, and eventual softening of the auto cycle can compress the combined ratio from the current exceptional level back toward normal, and the multiple will re-rate with it. Margin of safety here is thin. I would want a mid-teens pullback before calling it cheap on valuation alone.

Cheap signals 2
m30
Anchored PE suggests modest upside
The $267.78 anchored PE implies ~24% upside vs current $215.34 - real but not a margin-of-safety trade, more a fair-to-slightly-attractive read.
m25
Quality and earnings integrity raise deserved value
Fortress quality (80), shrinking share count, and high earnings quality (score 2, no haircut) justify a premium multiple - supports deserved value near the upper end of the fair range but does not make it cheap.
Rich / priced-in 3
m55
Composite FV is a runaway output
A $621 composite and $871 signal-adjusted FV vs $215 price implies 3-4x upside on a $124B mature insurer - not credible. DCF ($799) is extrapolating peak-cycle growth; I heavily discount both.
m45
Priced for continued perfection
PGR has ridden the hard auto market to a combined ratio well below industry; the multiple already embeds continued share gains and elite underwriting. Any mean-reversion in loss costs re-rates the stock.
m30
Cyclical business at cycle peak
2022 dip is a reminder underwriting cycles exist. Buying an insurer at peak combined-ratio conditions at a premium multiple is where valuation risk lives.
This is a great business at a fair-to-full price - the common, correct answer. The e2e $621 composite is not usable; the anchored PE of $268 is the honest ceiling on deserved value, and at $215 that is maybe 20% of upside with real cycle risk on the other side. I need it closer to $180 - a mid-teens pullback - before I would call it a valuation buy. Owning it here is a quality bet, not a mispricing bet.
Verify before trusting this (5)
  • Combined ratio trajectory next 2-4 quarters vs current exceptional level
  • Loss-cost inflation and severity trends in auto (BI, physical damage)
  • PIF growth deceleration or reacceleration
  • Reserve development - favorable or adverse
  • Any guidance on ceding, reinsurance costs, or CAT load assumptions
General Sentiment
+9
Balanced
tail √Σ 60 · head √Σ 50 · conf 6/10

The tape is modestly risk-on (regime +46, VIX 15.2) which is a background positive, but PGR's 0.26 beta means the market's mood barely moves this name either way. What matters here is the narrative, and PGR sits in a comfortable spot: a durable, moderate-intensity steady-compounder story with the bull case (share gains, Snapshot moat, digital distribution) still intact and freshly reinforced by a Q2 earnings event that emphasized bundled auto+home expansion. That is a mild tailwind - the story is working, not breaking. Against that, the narrative is already well-known and low-cult; there is no fresh euphoria to inflate it, and the bear framing (priced for perfection, combined-ratio pressure, litigation/inflation drag on auto) is a persistent, quiet headwind that caps upside enthusiasm. Analyst tone around the print appears constructive-to-neutral based on the metrics-vs-estimates coverage, without a visible upgrade wave. Net: a name being carried gently by tape and narrative, but nothing decisive pressing it in either direction right now.

Tailwinds 3
m25
Risk-on tape, muted transmission
Regime is mildly risk-on with a low VIX, but PGR's 0.26 beta means the tape barely reaches this name. Real but small lift.
m45
Durable steady-compounder narrative intact
The share-gain / Snapshot / digital-distribution story is moderate-intensity and durable, and the Q2 event reinforced the bundled auto+home expansion angle. Story is working, not cracking.
m30
Momentum tailwind
Strong positive multi-year momentum (18.8% CAGR, +6.6pp over 3y) keeps trend-followers and quality-momentum funds long, a persistent bid on a low-beta name.
Headwinds 3
m35
Priced-for-perfection framing
The bear narrative that PGR has already discounted years of share gains sits quietly in the background, capping enthusiasm and making any underwriting stumble asymmetrically punitive.
m30
Macro rate/valuation backdrop
10y at 4.63% and market PE 27.7 create a mild drag on any name trading at a premium multiple; PGR's defensive profile softens it, but does not eliminate it.
m20
Low cult, no narrative accelerant
Cult coefficient is low and intensity only moderate - there is no story-driven mania to lift the stock beyond fundamentals; sentiment upside is naturally limited.
Net pressure is close to neutral with a faint tailwind lean. The durable, moderate-intensity compounder narrative was just refreshed at the Q2 event and momentum remains firmly positive, but PGR's low beta neutralizes most of the risk-on tape and there is no cult euphoria to over-shoot on. The bear framing of 'priced for perfection' is a persistent low-grade cap on sentiment rather than an active headwind. I would call this Balanced with a mild tilt up - not a name sentiment is fighting, but also not one it is chasing.
Verify before trusting this (4)
  • Analyst target-revision direction post Q2 print - are estimates drifting up or being trimmed on combined-ratio commentary
  • Any sign of the auto-insurance narrative shifting from 'share gainer' to 'margin pressure' - would flip sentiment to headwind
  • Rotation flows: if the tape turns more risk-on/high-beta, PGR could be a source of funds and drift on a relative basis
  • Catastrophe/hurricane season headlines that could re-price the property expansion story
The market-wide tape + this name's exposure to it (beta / sector / narrative durability). Context on the non-fundamental pressure — not a call on the business or the price. processId: detail-general-sentiment
Growth Outlook
not run

This lens hasn't been run for this ticker yet.

The forward growth verdict — is the business itself likely to grow (next 2 quarters / year 1 / years 2–3), judged against its category and against printed expectations. The full horizon ladder + creme renders on the Growth Outlook card above. Not a call on the price (Valuation owns that) or the tape (Sentiment owns that).
Please log in to view trade setups
The Augustus trade-setup read is a members feature.
Log in
Lenses kept deliberately separate — Company Quality (price-agnostic), Valuation (price-conditional), General Sentiment (non-fundamental macro/narrative pressure), and Growth Outlook (the forward growth verdict). The scores are not blended. Filing-level items (convertibles, lock-ups, customer concentration) are v2 — see each lens's "verify."
Price Prediction
About flat -2.5% v0.6.0 View full prediction →

When we made this prediction on Aug 7, 2026, PGR was $215.34. We expect it to be $210.00 by Feb 2027, and we consider it great value under $180.00. This is an early model (v0.6.0) — the direction is more reliable than the exact price. Made Aug 7, 2026.

Price when predicted$215.34
Our estimate for Feb 2027$210.00-2.5%
Great value below$180.00
Price history shown (6 Months)

Blue is our prediction, starting the day we made it. Grey is a slower route to the same place — the same destination, taking longer. Black is the actual price, so you can see how we are doing.

Community AI Feedback
No community reviews yet for PGR. Be the first — hit How to Contribute, have any AI review this page, and paste its take back here.
My Notes personal — only you see this
v1.1.562 · 9b2927c4 · 2026-08-22 16:52:06